Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

March 16, 2011 07:01 ET

Allezoe (ALZM) Announces Founder of UNOS and Organ Sharing Expert to Join OTS Board of Advisors

FRISCO, TEXAS--(Marketwire - March 16, 2011) - Allezoe Medical Holdings (OTCBB:ALZM) is proud to announce that Gene A. Pierce will join the Organ Transport Systems Board of Advisors. Organ Transport Systems is a wholly-owned subsidiary of Allezoe.

Mr. Pierce is the Founder and Executive Director emeritus of United Network for Organ Sharing (UNOS) and SouthEast Organ Procurement Foundation; he is also widely hailed as the patriarch of organ sharing. Mr. Pierce's vision for the expansion of organ transplantation beyond local practice and into a national network resulted in UNOS, which connects transplant institutions, health advocacy groups, and individuals touched by organ transplantation or donation. Currently, all organ transplant recipients and donors must be registered with UNOS, making it a national clearinghouse for all US transplant data, an initiative instituted under his leadership.

Organ Transport Systems ("OTS") is focused on improving human donor organ procurement through better organ preservation technology, with its LifeCradle® product line. As a result of factors including shortcomings in the currently available preservation and transport methods, a low percentage of donated organs are actually utilized. By providing a safe and cost effective method to transport human organs for transplant purposes, OTS hopes to increase the percentage of donated organs that are utilized in transplantation.

Michael Holder, CEO of Organ Transport Systems says, "Gene is an expert in the dynamics of all the players in the organ transplant industry. We look forward to bringing his wealth of knowledge to bear on how OTS's organ preservation technology is introduced to and navigates the market. We are thrilled to have the opportunity to work closely with him, and to share this exciting development with our shareholders and the organ sharing community as a whole."

Pierce says, "There are tremendous opportunities to improve the preservation and transportation of donated organs. OTS has developed impressive technologies and with their collaborating research scientists have documented outstanding results in their pre-clinical animal studies. The implementation of these technologies in the real clinical setting will greatly advance the field for organ procurement organizations, transplant surgical teams, and most of all patient recipients."

In addition to his groundbreaking work creating the UNOS network, Mr. Pierce is the recipient of two honorary doctorates as well as several distinguished awards throughout his military and civilian careers.


This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact Information